(Total Views: 59)
Posted On: 03/12/2025 4:43:23 PM
Post# of 137
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients
Clene (NASDAQ: CLNN) Clene Inc. (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significantly extended survival for patients with ALS. The analysis compared patients receiving CNM-Au8 (Regimen C) to a large concurrent control group (Regimen A) and demonstrated a median survival increase of 6.5 months. The strongest survival benefit was observed in a subset meeting the planned Phase 3 RESTORE-ALS trial criteria, where CNM-Au8 extended median survival by 14.8 months. These findings reinforce CNM-Au8’s potential to enhance ALS patient outcomes as Clene prepares for its confirmatory Phase 3 trial in mid-2025.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) Clene Inc. (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significantly extended survival for patients with ALS. The analysis compared patients receiving CNM-Au8 (Regimen C) to a large concurrent control group (Regimen A) and demonstrated a median survival increase of 6.5 months. The strongest survival benefit was observed in a subset meeting the planned Phase 3 RESTORE-ALS trial criteria, where CNM-Au8 extended median survival by 14.8 months. These findings reinforce CNM-Au8’s potential to enhance ALS patient outcomes as Clene prepares for its confirmatory Phase 3 trial in mid-2025.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
